Icons / Logo / Facebook Created with Sketch. Icons / Logo / Google Created with Sketch. Icons / Logo / ORCID Created with Sketch. Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Hilary D. Marston
National Institutes of Health
21Publications
10H-index
387Citations
Publications 21
Newest
Published on Apr 17, 2019in The New England Journal of Medicine 70.67
Catharine I. Paules8
Estimated H-index: 8
,
Hilary D. Marston10
Estimated H-index: 10
,
Anthony S. Fauci169
Estimated H-index: 169
Measles in 2019 β€” Going Backward Recent increases in measles cases in the United States mirror patterns in other countries that had previously eliminated the virus. This resurgence is all the more frustrating since the disease is entirely preventable through vaccination.
Published on Feb 1, 2019in Vaccine 3.27
Kirsten Vannice9
Estimated H-index: 9
(WHO: World Health Organization),
M. Cristina Cassetti5
Estimated H-index: 5
(NIH: National Institutes of Health)
+ 6 AuthorsPhilip R. Krause27
Estimated H-index: 27
(CBER: Center for Biologics Evaluation and Research)
Abstract Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical disease endpoint efficacy studies. However, ZIKV is still circu...
Published on Sep 18, 2018in Annals of Internal Medicine 19.32
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health),
Carl W. Dieffenbach10
Estimated H-index: 10
(NIH: National Institutes of Health),
Anthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Published on Aug 23, 2018in The New England Journal of Medicine 70.67
Catharine I. Paules8
Estimated H-index: 8
,
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health)
+ 1 AuthorsAnthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Tickborne Diseases The burden of tickborne diseases is growing substantially and seems likely to continue to do so. Prevention and management are hampered by suboptimal diagnostics, lack of treatment options for emerging viruses, and a paucity of vaccines.
Published on Apr 19, 2018in The New England Journal of Medicine 70.67
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health),
Catharine I. Paules8
Estimated H-index: 8
(NIH: National Institutes of Health),
Anthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Monoclonal Antibodies for Infectious Diseases Research advances could facilitate use of monoclonal antibodies for emerging infectious diseases β€” in treatment of infected individuals, targeted prophylaxis to protect high-risk individuals, and targeted prophylaxis to interrupt transmission in average-risk populations.
Published on Dec 5, 2017in Annals of Internal Medicine 19.32
Catharine I. Paules8
Estimated H-index: 8
(NIH: National Institutes of Health),
Robert W. Eisinger6
Estimated H-index: 6
(NIH: National Institutes of Health)
+ 1 AuthorsAnthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Published on Nov 14, 2017in JAMA 51.27
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health),
Catharine I. Paules8
Estimated H-index: 8
(NIH: National Institutes of Health),
Anthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Published on Oct 1, 2017in Immunity 21.52
Catharine I. Paules8
Estimated H-index: 8
(NIH: National Institutes of Health),
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health)
+ 2 AuthorsAnthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
Development of a universal influenza vaccine is a research priority for the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. To facilitate this goal, we convened a workshop in Rockville, Maryland to identify knowledge gaps in influenza research and develop strategies to fill them.
Published on Sep 29, 2016in The New England Journal of Medicine 70.67
Hilary D. Marston10
Estimated H-index: 10
,
Nicole Lurie52
Estimated H-index: 52
+ 1 AuthorsAnthony S. Fauci169
Estimated H-index: 169
The scientific feasibility of developing a safe, effective Zika vaccine doesn't ensure successful development. An efficient development pathway must be delineated, including better ways to evaluate vaccine candidates for intended target populations.
Published on Feb 1, 2016in Clinical Trials 2.26
H Cliffordlane72
Estimated H-index: 72
(NIH: National Institutes of Health),
Hilary D. Marston10
Estimated H-index: 10
(NIH: National Institutes of Health),
Anthony S. Fauci169
Estimated H-index: 169
(NIH: National Institutes of Health)
12